Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $10.00 by Analysts at KeyCorp

Recursion Pharmaceuticals (NASDAQ:RXRX) had its price objective dropped by stock analysts at KeyCorp from $12.00 to $10.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp’s price target suggests a potential upside of 37.74% from the company’s previous close.

Separately, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.75.

Recursion Pharmaceuticals Trading Down 3.1 %

RXRX traded down $0.23 on Wednesday, reaching $7.26. 12,122,098 shares of the company traded hands, compared to its average volume of 16,940,623. The company has a market cap of $2.84 billion, a P/E ratio of -4.75 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a one year low of $5.60 and a one year high of $15.74. The firm has a fifty day simple moving average of $6.90 and a two-hundred day simple moving average of $7.02.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s revenue was up 147.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.43) EPS. As a group, equities research analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the transaction, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,288,380.78. This represents a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the sale, the director now owns 7,089,007 shares of the company’s stock, valued at approximately $47,283,676.69. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,341 shares of company stock valued at $393,490. 15.75% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its position in shares of Recursion Pharmaceuticals by 16.4% in the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after purchasing an additional 4,626,268 shares during the last quarter. State Street Corp raised its holdings in shares of Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. FMR LLC lifted its stake in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after buying an additional 170,810 shares during the period. Geode Capital Management LLC increased its position in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after acquiring an additional 656,003 shares during the period. Finally, Lingotto Investment Management LLP raised its stake in Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock worth $27,563,000 after acquiring an additional 1,500,000 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.